MDA-MB-436 Xenograft Model Service for Breast Cancer

The MDA-MB-436 xenograft model serves as a highly validated, clinically relevant in vivo translational platform specifically engineered to evaluate candidate therapeutics targeting BRCA1-deficient, aggressive triple-negative breast cancers (TNBC). Alfa Cytology delivers a comprehensive, end-to-end MDA-MB-436 xenograft model service, combining fully authenticated cellular resources with standardized inoculation workflows to accelerate preclinical oncology drug discovery timelines.

Overview of MDA-MB-436 Xenograft Model for Breast Cancer

The MDA-MB-436 cell line is an essential human mammary carcinoma model in preclinical oncology, classified within the claudin-low/mesenchymal-like molecular subtype of TNBC. Originally derived from the pleural effusion of a patient with advanced breast adenocarcinoma, this model is molecularly defined by the lack of ER, PR, and HER2 expression. Crucially, MDA-MB-436 harbors a significant genetic hallmark: a complex homozygous mutation in the BRCA1 gene (specifically a 5382insC mutation resulting in a truncated, non-functional protein). This defect leads to severe homologous recombination deficiency (HRD), rendering the model exceptionally sensitive to DNA-damaging agents and making it an indispensable test matrix for validating PARP inhibitors, platinum-based chemotherapies, and novel targeted therapies addressing genetic instability or synthetic lethality pathways.

When established in vivo as a xenograft in immunodeficient mice, MDA-MB-436 cells develop into poorly differentiated, high-grade solid tumors that accurately recapitulate the genomic instability, hyper-aggressive behavior, and clinical microenvironment of human BRCA1-mutated malignancies. Unlike many fastidious luminal models, MDA-MB-436 exhibits highly predictable tumor take rates and steady in vivo growth kinetics without requiring exogenous hormone supplementation.

Fig 1. Effect of Anthos on cell viability, cell-cycle progression, and apoptosis. (Aqil F, et al., 2021)

Cell Line Information: MDA-MB-436

The MDA-MB-436 cell line maintains a distinct spindle-shaped, mesenchymal morphology in vitro and reliably preserves its primary TNBC receptor profile and BRCA1 mutational signatures upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MDA-MB-436 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including HRD signature profiling and PK/PD assessments. Leveraging our expertise in BRCA1-deficient triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MDA-MB-436 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MDA-MB-436 xenograft model:

• Cell Culture & Quality Control: MDA-MB-436 cells are cultivated in cell-bank-certified growth media under optimized parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Selection & Acclimatization: Standardized immunocompromised mice are selected based on specific study designs and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability MDA-MB-436 cells is prepared and blended with a verified biological matrix carrier to optimize spatial distribution and enhance cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic mammary fat pad routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. MDA-MB-436 Xenograft Model Construction Workflow

Case Study - MDA-MB-436 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MDA-MB-436 xenograft model was successfully utilized to evaluate the therapeutic efficacy of a novel small-molecule PARP inhibitor targeting BRCA1-deficient triple-negative breast cancer. Under optimized modeling protocols, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy.

Our Advantages

Choosing the right partner for your aggressive, BRCA1-deficient triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation protocols ensuring uniform tumor growth and minimizing variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, HRD signature profiling, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, BRCA1-deficient triple-negative breast cancer using the robust MDA-MB-436 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.